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Background: Colorectal cancer is the second leading cause of cancer death in the United States, with over 50,000
deaths estimated in 2014. Molecular profiling for somatic mutations that predict absence of response to anti-EGFR
therapy has become standard practice in the treatment of metastatic colorectal cancer; however, the quantity and
type of tissue available for testing is frequently limited. Further, the degree to which the primary tumor is a faithful
representation of metastatic disease has been questioned. As next-generation sequencing technology becomes
more widely available for clinical use and additional molecularly targeted agents are considered as treatment
options in colorectal cancer, it is important to characterize the extent of tumor heterogeneity between primary
and metastatic tumors.
Results: We performed deep coverage, targeted next-generation sequencing of 230 key cancer-associated genes
for 69 matched primary and metastatic tumors and normal tissue. Mutation profiles were 100% concordant for KRAS,
NRAS, and BRAF, and were highly concordant for recurrent alterations in colorectal cancer. Additionally, whole
genome sequencing of four patient trios did not reveal any additional site-specific targetable alterations.
Conclusions: Colorectal cancer primary tumors and metastases exhibit high genomic concordance. As current
clinical practices in colorectal cancer revolve around KRAS, NRAS, and BRAF mutation status, diagnostic sequencing
of either primary or metastatic tissue as available is acceptable for most patients. Additionally, consistency between
targeted sequencing and whole genome sequencing results suggests that targeted sequencing may be a suitable
strategy for clinical diagnostic applications.Background
Precision oncology relies on the accurate characterization
of targetable oncogenic mutations present at the time of
metastatic disease. However, it is often challenging to ob-
tain biopsies of metastatic tumors, and it is still preferable
to use the least invasive screening methods possible.
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unless otherwise stated.heterogeneity in several solid tumor types raises concerns
that molecular profiling of primary tumors may not be
representative of metastatic disease [1-3]. In colorectal
cancer (CRC), comparative lesion sequencing of a small
number of cases found a high degree of concordance
between primary tumors and metastases [4]. In contrast,
a recent study of 21 patients using next generation
sequencing reported a high degree of mutational dis-
cordance between primary and metastatic samples [5].
We previously showed that when analysis was performed
on the invasive compartment of primary tumors, KRAS,
NRAS, BRAF, and TP53 mutations were highly concordant
between primary and metastatic tumors [6]. This studyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of CRC cases subjected to
targeted sequencing
Clinical characteristic N = 69



















Prior treatment 39 (56.5%)
Both tumors 27 (39%)
Primary only 1 (1.5%)
Metastasis only 11 (16%)
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primary tumor for molecular profiling may be suitable for
clinical decision making in metastatic CRC. However, this
conclusion was based on the analysis of only a small num-
ber of genes by mass-spectrometry based genotyping and
Sanger sequencing.
To determine the extent of additional, clinically relevant
genetic heterogeneity, we extended this analysis by
performing high coverage, next generation sequencing
analysis of 230 cancer-associated genes. Specifically,
we performed targeted sequencing on primary, metastatic,
and normal tissue from 69 colorectal cancer patients. We
found that there was a high degree of concordance with
regard to early occurring and recurrent mutations. KRAS,
NRAS, and BRAF mutations were always identical in both
the primary and metastatic tumors. Whole genome se-
quencing of two concordant and two discordant patient
sets upheld the targeted sequencing results and revealed
few additional recurrent mutations. In sum, these data
suggest that for current clinical practices, either primary
or metastatic tissue can be selected for testing, and tar-
geted sequencing of key cancer genes is a suitable strategy
for identifying clinically actionable alterations.
Results
Patient selection
We analyzed 69 patient trios of primary CRC and
matched metastases and normal tissue using a custom
capture-based deep sequencing assay (IMPACT, see
Methods). The assay covers all protein-coding exons of
230 actionable or cancer-related genes (mean target
coverage 692X). Only microsatellite-stable tumors were
included in the study. Sixty-two (90%) patients presented
with stage IV disease (Table 1). In 52 (75%) patients, the
primary tumor and metastasis were resected at the same
time (concurrent). Among the remaining 17 cases the
mean interval time between resections was 15.3 months.
Thirty (43%) patients were chemonaive prior to resection
(Table 1). None of the treated patients received an anti-
EGFR therapy prior to resection.
Mutation profiles are highly concordant between primary
and metastatic tumors
Overall, we detected 434 distinct non-synonymous som-
atic mutations and indels (Additional file 1: Table S1). The
mutation profile was consistent with the expected muta-
tion frequencies for non-hypermutated samples reported
by The Cancer Genome Atlas (TCGA) [7] (Figure 1A).
We observed APC and TP53 alterations at higher preva-
lence than the TCGA reported, whereas NRAS mutations
were observed less frequently in our study compared to
the TCGA. Of the 434 total mutations, 344 (79%) were
shared between patient-matched tumors (Figure 1B-C,
Additional file 2: Figure S1). No discordant mutationswere observed in KRAS, NRAS, or BRAF in our cohort.
Further, among the mutations in the genes reported by the
TCGA to be significantly mutated in non-hypermutated
tumors (Figure 1B; 247/434, 57%), there was very high
(93%, 229/247) concordance between primary tumors and
matched metastases. The 18 private mutations, defined as
mutations called only in the primary or the metastatic
tumor, were found in APC (n = 7), PIK3CA (n = 5),
SMAD4 (n = 3), and TP53 (n = 3). The majority (n = 5)
of the private mutations in APC were secondary muta-
tions in cases that shared a clonal APC mutation. One
‘primary-specific’ event was detectable on further review
at a low frequency in the metastasis by comparative ana-
lysis. In the remaining case, an APC mutation private to
the primary tumor was likely lost in a chromosomal dele-
tion in the paired metastasis (Figure 2). Our findings con-
firm that genetic alterations that occur early in colorectal
carcinogenesis, namely mutations in APC, KRAS, NRAS,
and BRAF, persist through tumor evolution and show an
exceedingly high level of concordance between primary
tumor and metastases [8].
Despite the overall high concordance in mutation






































































































































































































































































































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 Mutation patterns are concordant between primary and metastatic tumors and consistent with TCGA. (A) Most commonly
mutated gene frequencies are similar to those of the TCGA non-hypermutated cohort, with minor differences likely due to increased sequencing
depth and more advanced disease. (B, C) Mutations are highly concordant between primary and metastatic tumors. Shared mutations are in dark
purple, private to primary is light red, private to metastasis in light blue. Mutations that are loss-of-function (nonsense, frameshift, or splice site) or
that occur in at least five samples in Cosmic are marked with an orange dot.
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of this discordance could be explained by intra-tumor
heterogeneity, we sequenced 97 additional samples from
spatially separate regions of the primary tumors (n = 62)
and metastases (n = 37) from 22 patients, encompassing
46 discordant mutations. All 97 samples were derived
from formalin fixed paraffin embedded (FFPE) tissue and
reviewed for morphology and tumor cellularity. Sequencing
of multiple regions and samples resolved 17/46 discordant
mutations, including 12/22 (55%) mutations that were ori-
ginally detected only in the metastasis but were subsequently
found to be subclonal in the primary tumor (Additional file
1: Table S1). Altogether these results suggest that the small
proportion of discordant mutations we observed may itself
be an overestimate of the true discordance when account-
ing for intra-tumor heterogeneity.
Private oncogenic alterations are occasionally detected
Convergent phenotypic evolution was observed in two pa-
tients harboring distinct mutations in individual genes,
one involving independent mutations in TP53 (R248Q
and Y163*) and the other involving separate hotspot mu-
tations in PIK3CA (E542K and E545K, Additional file 2:
Figure S2). Three additional private events were observed
in PIK3CA including two E545K mutations specific to the
primary tumor and one in-frame deletion at N107 specificFigure 2 Phenotypic concordance of mutations. In patient 10, the prim
tumor (A). (B) However, the tumor/normal ratio per exon of coverage on c
the metastatic tumor, yielding identical phenotypic results. Similar results wto the metastasis. Private mutations of unknown signifi-
cance were also found in PIK3CD, PIK3CG, PIK3C2G,
PIK3R1, and PTEN. Four of these PI3K pathway events
were found in other regions, indicative of subclonality.
These results suggest that despite the overall high level of
genomic concordance between primary and metastatic
CRC, heterogeneity in potentially actionable genes, such
as those within the PI3K pathway, is present in at least a
subset of patients. This finding could have therapeutic im-
plications given the ongoing evaluation of PI3K inhibitors
in clinical trials as well as the potential benefit of aspirin
therapy in CRC patients harboring PIK3CA mutations [9].
Notably, we also found genetic events private to the me-
tastasis in three patients lacking KRAS, NRAS, and BRAF
mutations. In two cases, MAP2K1 (MEK1) mutations
(A106T and Q56P) were detected only in the metastatic
sample (Additional file 2: Figure S3). While A106T has not
been described, Q56P is a recurrent mutation. Transfection
of a GFP-tagged MAP2K1 Q56P plasmid into human em-
bryonic kidney 293H cells resulted in hyperactivation of
ERK signaling to a similar degree as other known activating
mutations of MAP2K1 (Figure 3A). By contrast, transfection
of A106T did not affect signaling (Additional file 2: Figure
S4). In another patient, we found a gain of chromosome 7p,
which included the CARD11, ETV1, IKZF1, and EGFR
genes in the metastasis but not in the primary tumorary tumor harbors a nonsense mutation not found in the metastatic
hromosome 5 shows that the exons of APC (red dots) are deleted in


















Figure 3 Metastatic-specific RTK-RAS activating events in RAS/RAF wildtype tumors. In several tumors lacking KRAS, NRAS, or BRAF mutations,
additional events in the RTK-RAS pathway were identified. (A) In patient 19, a metastatic-specific MAP2K1 p.Q56P mutation was identified. Transfection of
GFP-tagged MAP2K1 plasmids demonstrate that the p.Q56P mutation hyperactivates downstream signaling to the same level as the known p.K57N
mutation. (B) In patient 3, chromosome 7p is specifically amplified in the metastatic tumor. (C) FISH analysis confirms regions of high level amplification
of EGFR in the metastatic tumor (right) while the primary tumor only shows 7p polysomy (left).
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analysis of both samples. Both the primary tumor and
metastasis displayed cells with 7p polysomy; however, the
metastasis also contained regions of high-level EGFR amp-
lification not observed within any region of the primary
tumor (Figure 3C). These findings collectively suggest that
in the absence of RAS mutations, analysis of a metastasis
may reveal potentially actionable alterations within other
members of the EGFR-RAS signaling pathway.Clinical correlates of mutational concordance
We next examined whether mutational concordance was
correlated with major clinical characteristics (Additional
file 3: Table S2). We observed no significant difference
in the number of mutations or degree of mutational con-
cordance for cases with different primary tumor locations
(right colon, left colon, or rectum) or for cases with
different time intervals between primary and metastasis
resections (concurrent versus subsequent; Additional
Figure 4 Whole genome analysis of mutational concordance.
(A) Concordant and discordant non-synonymous mutations and
indels for four CRC patients. (B) Percent of protein coding alterations
per sample for IMPACT and WGS results. Patients 3 and 19 were
discordant by IMPACT and remain so by WGS, while patients 14 and
54 remain largely concordant.
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survival differences for patients with concordant and
discordant mutation profiles (Additional file 2: Figure S5).
However, among patients whose tumors were concur-
rently resected, those that did not receive prior treatment
were more likely to harbor discordant mutations (22/28,
79%) compared to those that received prior therapy (11/24,
46%; chi-square P = 0.01. Patients without prior therapy
also had a higher total number of mutations, although
the difference was not statistically significant (6.6 vs.
5.8, P = 0.1). These differences may be due to either gen-
eral tumor debulking and/or decreased tumor heterogen-
eity from effective drug treatment [10]. In accordance
with this hypothesis, the primary tumor size in patients
receiving prior treatment was slightly smaller than in
chemonaive patients (4.2 vs. 5.2 cm, T test P = 0.02).
Additionally, pre-treated patients with concurrently
resected tumors were less likely to harbor primary-only
mutations than patients with subsequent resections where
only the metastasis received treatment (6/24, 25% vs. 7/11,
64%; chi-square P = 0.03).
Whole genome analysis reveals consistent mutation patterns
While our capture-based assay encompasses all well-
established targetable or actionable genes in CRC, this
approach by definition would fail to identify discordant
mutations not included in the assay design. To determine
whether our results were representative of the level of
mutational concordance genome-wide, we performed
whole genome sequencing (WGS) of two cases where
the primary tumor and metastasis were concordant by
IMPACT analysis (patients 14 and 54) and two cases
that harbored discordant mutations (patients 3 and 19,
with one and three discordant mutations by IMPACT,
respectively). Given the slight disparity in mutations
for pre-treated versus chemonaive tumors, we chose the
patients such that within each group, one patient’s tumors
were chemonaive (patients 3 and 54) and the other
patient’s tumors had received prior treatment (patients 14
and 19). Primary and metastatic tumors were sequenced
to >80× coverage, and matched normal controls were se-
quenced to >40× coverage. All SNVs and indels detected
at higher than 5% allele frequency by IMPACT were de-
tected in our WGS analysis, and no additional mutations
in the 230 genes were identified, providing independent
validation of the results produced by both methods.
The two patients whose primary and metastatic tumors
exhibited discordance by IMPACT analysis displayed
significant discordance at the WGS level as well (Figure 4,
Additional file 2: Figure S6). Comparing all somatic muta-
tions genome-wide, patients 3 and 19 had only 38% and
25% shared mutations, respectively. This rose only slightly
to 46% and 32% when considering only non-synonymous
exonic mutations (Additional file 5: Table S4). Patient 19harbored nine loss-of-function mutations (nonsense, frame-
shift, or splice site) private to the metastasis. Four other
metastasis-specific events, including MAP2K1 Q56P de-
tected by IMPACT, are represented in the COSMIC
database. Patient 3 harbored six metastasis-specific loss-
of-function mutations and three metastasis-specific recur-
rent mutations also present in COSMIC. A novel PTK7
Q304* mutation was particularly noteworthy, as this pro-
tein inhibits canonical Wnt signaling through binding of
the frizzled receptor [11]. However, no nonsense muta-
tions were reported in PTK7 in TCGA for CRC, and thus
this event, though potentially functional, is rare in CRC.
Patient 3 also harbored a metastasis-specific missense mu-
tation in the transcriptional regulation domain of SMAD3
in addition to a metastasis-specific SMAD4 mutation de-
tected by IMPACT.
In contrast, WGS of the paired tumors from the two
patients who exhibited 100% concordance by IMPACT
analysis (patients 14 and 54) showed a high degree of
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As above, the level of concordance increased even fur-
ther upon restricting the analysis to non-synonymous
protein-coding mutations (87% and 86% shared) and
loss-of-function mutations (91% and 91% shared). For
patient 54, a single discordant mutation in RUNXT1 was
the only discordant alteration present in COSMIC, and
no discordant mutations were nonsense or splice-site
mutations. Similarly none of the discordant mutations in
patient 14 are currently represented in the COSMIC
database. Case 14 was notable in that analysis by IMPACT
revealed no mutations in both the beta-catenin and RAS
pathways, although the tumor harbored an amplification
of CDK8, which has be shown to dysregulate the WNT/
beta-catenin pathway [12]. No additional beta-catenin
pathway alterations were identified by WGS; however,
two nonsense mutations in RASA1 (C372* and R679*)
were detected in the both primary and metastatic sam-
ples. RASA1, a negative regulator of RAS, was altered in
2% of CRC TCGA samples, with mutations in this gene
mutually exclusive of KRAS and NRAS mutations. This
result prompted the addition of capture probes for the
RASA1 gene in our current version of IMPACT and
highlights the utility of whole genome sequencing to
identify rare alterations in driver pathways such as
RAS in tumors pan-negative for the more commonly
mutated genes.
Discussion
We performed deep sequencing of 230 cancer-associated
genes in 69 primary CRC tumors and matched metastases
to define the mutational concordance of these genes in
primary and metastatic tumors. We identified a pattern of
genomic alterations consistent with prior studies of CRC,
including frequent mutations in the APC, TP53, and
KRAS genes [4,7]. Mutations in TP53 were more prevalent
in our series than TCGA. TCGA analyzed only primary
tumors, the majority of which were derived from patients
with stage 1 to 3 disease, whereas all patients in our co-
hort by definition had metastatic disease. This difference
is likely the basis for both the higher prevalence of TP53
mutation and the lower prevalence of NRAS mutations in
our cohort versus TCGA. The higher prevalence of certain
mutations observed from IMPACT may also be the result
of greater sensitivity for mutation detection afforded
by deeper sequence coverage (mean coverage of 692X).
Although we did not observe significant differences in
the degree of heterogeneity between those tumors that
were resected concurrently or subsequently, future
studies are required to determine the extent to which
systemic treatments result in preferential selection of
specific mutational events.
The only major clinical feature that seemed to correlate
with mutational concordance was whether the tumors hadreceived prior treatment. In patients where tumors were
concurrently resected, chemonaive tumors were more
likely to have private mutations than pre-treated tumors.
Similarly, patients with pre-treated metastatic tumors sub-
sequently resected were more likely to harbor primary-
only mutations than patients with pre-treated concurrent
resections. These findings raise the possibility that prior
treatment results in a decrease of apparent tumor het-
erogeneity, though larger studies are needed to further
explore this hypothesis.
Overall, our exon capture data indicate a high degree
of concordance in mutational profiles, especially when
considering events that occur early in colorectal carcino-
genesis. Further, multiple examples of discordance involved
parallel evolution demonstrated by independent distinct
mutations in the same gene [13]. A subsequent whole
genome analysis of four paired primary and metastatic
samples further suggested that concordance by IMPACT
is a good surrogate of genome-wide mutational concord-
ance. Notably, mutations in KRAS, NRAS, and BRAF
were 100% concordant between primary tumors and
metastases in our cohort, which is consistent with
prior studies [6,14-16]. These results are also consist-
ent with the recommendation that molecular testing of
the primary tumor is appropriate in most clinical sce-
narios. Exceptions would include patients with a his-
tory of multiple primary tumors or polyps and patients
in which interval drug treatment may result in clonal
selection of clinically actionable mutations [6]. An ex-
ample of the latter would be treatment with anti-EGFR
therapy, which has been shown to promote the selec-
tion of RAS mutant subclones in tumors that are
otherwise KRAS, NRAS, and BRAF wild-type [17,18].
In primary tumors lacking KRAS, NRAS, or BRAF
mutations, we did identify occult alterations in the
EGFR/RAS pathway that in some patients were private
to the metastatic tumor. Discordant mutations were
also occasionally observed in components of the PI3K
pathway, which could be clinically important as selective
inhibitors of the pathway are being actively studied in
patients with CRC.
Finally, we found that targeted sequencing was sufficient
to identify the most clinically actionable alterations found
by WGS. This result suggests that an updated IMPACT test
may be a viable time- and cost-saving alternative to WGS
for molecular profiling of CRC patients.
Conclusions
Inter- and intra-tumor heterogeneity, a growing concern in
the molecular diagnostics field, is apparent in CRC. How-
ever, in patients who have not been treated with anti-EGFR
therapies, the current clinically actionable genes,
KRAS, NRAS, and BRAF, are 100% concordant be-
tween primary and metastatic tissues. As the mutational
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nostic testing from either tissue site as available is appro-
priate in most clinical scenarios. Additionally, targeted
sequencing is becoming a more common practice in re-
search and clinical settings, and our results demonstrate
the clinical utility of this approach both through compari-
son of primary and metastatic tissue and similarities of
results to whole genome sequencing.
Methods
Samples
With Institutional Review Board approval (WA0129-12)
and compliance with the Helsinki Declaration, we analyzed
69 matched trios (normal, primary, and metastatic tissues)
from patients undergoing resection at our institution where
frozen tissue was available. The set was enriched for patients
with stage IV disease at diagnosis to decrease potential dis-
cordant alterations caused by time. All specimens were
reviewed for histological verification of a colorectal adeno-
carcinoma diagnosis and to ensure greater than 50% tumor
content. Macrodissection was performed on specimens with
less than 50% viable tumor to minimize stromal contamin-
ation. Normal DNA was obtained from normal colon tissue
located at least 15 cm away from the tumor. Normal and
tumor DNA were extracted from shaved sections cut from
frozen tissue blocks using the Qiagen DNeasy Blood & Tis-
sue Kit. In two cases where the frozen section contained an
adenoma, invasive regions of the primary were macrodis-
sected from formalin-fixed paraffin-embedded sections, and
DNA was extracted using the Qiagen DNeasy Blood & Tis-
sue Kit modified for deparaffinization and these sequencing
results were used in place of the original frozen data. Add-
itional regions for determination of private mutations were
selected from available FFPE tissue blocks and similarly
macrodissected and prepared.
Microsatellite testing
The microsatellite instability (MSI) status was determined
for each case using a 5-microsatellite marker (BAT25,
BAT26, D17S250, D2S123, and D5S346) genotyping
platform according to a standard protocol [19]. Fluoro-
phore-labeled primers were designed (Applied Biosystems)
targeting the five loci. All microsatellite loci were amplified
for matched normal and tumor DNA in a multiplex
polymerase chain reaction (PCR) and submitted for
genotyping to the MSKCC Genomics Core. Microsatellite
marker stability was analyzed using Peak Scanner™ soft-
ware. MSI status was categorized as microsatellite stable if
all markers were stable, MSI-low if <30% of markers were
unstable, and MSI-high if ≥30% of markers were unstable.
IMPACT targeted sequencing
Library preparation and sequence analysis is as previously
described [20]. Briefly, 100 to 500 ng DNA from frozen orformalin fixed paraffin embedded (FFPE) tissue was pre-
pared using NEBNext DNA Library Prep Kit for Illumina
with Kapa HiFi DNA Polymerase for PCR steps. A total of
100 ng resulting library was pooled in sets of 12 to 24
samples for capture with custom Nimblegen probes. Each
pool was sequenced in a single lane of an Illumina HiSeq
2000. Resulting fastq files were aligned according to best
practice with BWA [21], GATK, Picard [22], and Samtools
[23]. Mutations and indels were called with Mutect [24] and
GATK SomaticIndelDetector, respectively, and annotated
with Oncotator [25] and Cosmic v65 [26]. Only non-
synonymous mutations above 5% allele frequency in exonic
regions were retained. For primary or metastasis-specific
mutations, the allele counts at the corresponding site in the
alternate sample were examined. If the mutant allele was
present in at least 3 total reads and at least 2% of all reads,
the event was labeled as ‘both’ primary and metastasis by
comparative analysis. Copy number analysis was performed
using average read depth from GATK, loess-normalized for
GC content, and compared to diploid normal.
Cell lines and culture
Human embryonic kidney 293H cells were maintained
in DME-HG medium supplemented with 10% FBS, 2 mM
glutamine, and 50 units/mL each of penicillin and
streptomycin. MAP2K1 mutations were generated from the
MEK1-GFP plasmid (Addgene, 14746) using the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene) as
recommended. All mutant plasmids were verified by
DNA sequencing. 293H cells were seeded for 70% to
90% confluency at the time of transfection in the culture
medium without penicillin and streptomycin overnight.
Cells were transiently transfected with wild-type or
mutant MAP2K1 DNA using the Lipofectamine 2000
Transfection Reagent as recommended.
Western blot analysis
At 24 h post transfection, cells were collected and lysed in
1% NP-40 lysis buffer and processed for immunoblotting
as previously described [27]. Rabbit polyclonal antibodies
recognizing phosphorylated Erk1/2 (Thr202/Tyr204), Erk1/
2, phosphorylated p90RSK (Thr359/Ser363), and phosphor-
ylated p90RSK (Ser380) were obtained from Cell Signaling.
Rabbit monoclonal antibodies recognizing RSK1/2/3, GFP,
and GAPDH were obtained from Cell Signaling. After
incubation with horseradish peroxidase-conjugated
secondary antibodies, proteins were detected by chemilu-
minescence (SuperSignal West Dura Chemiluminescent
Substrate, Thermo Scientific) and visualized using the Fuji
LAS-4000 (GE Life Sciences).
Fluorescence in situ hybridization
Fluorescence in situ hybridization was performed by the
MSKCC Molecular Cytogenetics Core using BAC clone
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the EGFR locus in 7p11, both labeled by nick translation
with Red dUTP, together with a chromosome 7 centro-
meric repeat probe (p7t1) labeled with Green dUTP (Enzo
Life Sciences, supplied by Abbott Molecular). Initial
hybridization showed weak FISH signals against a high level
of background autofluorescence. Fresh probe was prepared
and new slides were hybridized. FISH signals for the second
hybridization were much stronger but the background au-
tofluorescence was still high. Images stacks (9× 0.5 um
slices for Red & Green) were captured through the depth of
the tissue for recording and analysis. R/G signal ratios were
scored in representative tumor fields with a minimum of 30
nuclei, where possible.
Whole genome sequencing
Five micrograms of DNA from patient-matched frozen
primary tumor, metastatic tumor, and normal tissue for
EV-003, EV-014, EV-019, and EV-054 were sent for
whole genome sequencing at the New York Genome
Center (NYGC) and Illumina. Median coverage was 87X
for tumors and 50X for normals. Mutations were called
on BAM files produced by the Illumina CASAVA align-
ment pipeline, using Strelka [28]. These mutations were
then genotyped on BAM files produced by the BWA
aligner, using GATK Unified Genotyper [21,29]. Calls
with fewer than 3 reads or 5% frequency in either the
primary and metastatic tumor were removed, as well as
those that were less than five times the frequency in the
normal tissue. Remaining calls were annotated for the
canonical isoform using Oncotator and COSMIC v65 [26].
Data availability
Data are publically available through dbGaP (accession
phs000790.v1.p1) and the Memorial Sloan Kettering
Cancer Center cBioPortal for Cancer Genomics ([30];
study ‘Colorectal Adenocarcinoma Triplets’) [31].
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mutation. Figure S4. Western blot analysis of MAP2K1 A106T plasmid.
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